Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Compound trial record
Compound · clinical trials

Ecnoglutide clinical trials

Also listed in trial records as XW003, VRB-101
Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 7 trials in our China, Japan and Australia registers that name Ecnoglutide as an intervention. Synced 9 Nov 2026
7Current trials
5Recruiting now
2Lead sponsors
3Country registers
At a glance

Ecnoglutide is named as an intervention in 7 current clinical trials in our China, Japan and Australia registers. 5 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Hangzhou Sciwind Biosciences Co., Ltd (6). The most-studied condition is Obesity.

How Ecnoglutide works

All drug targets →
Diseases it has been tested for in clinical trials, by furthest phase
  • OverweightPhase 3
  • Obesity disorderPhase 3
  • Obstructive sleep apnea syndromePhase 3
  • Type 2 diabetes mellitusPhase 3
  • Diabetes mellitusPhase 1
  • Metabolic dysfunction-associated steatohepatitisPhase 1

Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL5095115, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 13970, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.

Patient leaflets for Ecnoglutide

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

  • UK
    United Kingdom: Search MHRA Products
    Patient information leaflets and SmPCs for UK-licensed products.
  • US
    United States: Search DailyMed
    FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

  • Recruiting571%
  • Not yet open114%
  • Active, closed114%

Trials by phase

  • Phase 3457%
  • Phase 1/2114%
  • Phase 2114%
  • Phase 1114%
01

Clinical trials of Ecnoglutide

7 trials
StudyPhaseStatusLead sponsorRegisters
A Study of XW003 in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure Therapy
NCT07387094 · ClinicalTrials.gov ↗ · OSA - Obstructive Sleep Apnea, Obesity
Phase 3 Recruiting Hangzhou Sciwind Biosciences Co., Ltd China
A Study of XW003 in Obese Participants With Obstructive Sleep Apnea Receiving Positive Airway Pressure Therapy
NCT07434050 · ClinicalTrials.gov ↗ · OSA - Obstructive Sleep Apnea, Obesity
Phase 3 Recruiting Hangzhou Sciwind Biosciences Co., Ltd China
A Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA)
NCT07734311 · ClinicalTrials.gov ↗ · Knee Osteoarthritis, Obesity
Phase 3 Recruiting Hangzhou Sciwind Biosciences Co., Ltd China
A Phase Ib/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity
NCT07243171 · ClinicalTrials.gov ↗ · Overweight and/or Obesity, Weight Management
Phase 1/2 Recruiting Hangzhou Sciwind Biosciences Co., Ltd China, Japan
A Trial of Oral VRB-103 Alone or in Combination With Oral Ecnoglutide (VRB-101) in Participants With Obesity or Overweight
NCT07628127 · ClinicalTrials.gov ↗ · Obesity, Overweight
Phase 1 Recruiting Verdiva Bio Dev Limited Australia
A Study of Ecnoglutide Injection in Overweight or Obese Chinese Adolescents
NCT07836270 · ClinicalTrials.gov ↗ · Adolescents With Obesity, Adolescents With Overweight & Weight-related Comorbidities
Phase 3 Not yet open Hangzhou Sciwind Biosciences Co., Ltd China
A Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)
NCT07073417 · ClinicalTrials.gov ↗ · Obesity, Weight Management
Phase 2 Active, closed Hangzhou Sciwind Biosciences Co., Ltd China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

02

Conditions studied with Ecnoglutide

8 conditions
Obesity5Weight Management2OSA - Obstructive Sleep Apnea2Adolescents With Obesity1Adolescents With Overweight & Weight-related Comorbidities1Overweight and/or Obesity1Knee Osteoarthritis1Overweight1
03

Sponsors

lead sponsor per trial
Lead sponsorTrials
Hangzhou Sciwind Biosciences Co., Ltd6
Verdiva Bio Dev Limited1
04

By country register

RegisterTrialsRecruiting
Clinical trials in China64
Clinical trials in Japan11
Clinical trials in Australia11

A trial with sites in more than one country appears in each of those registers.

05

Related compounds

06

Questions about Ecnoglutide trials

How many clinical trials are testing Ecnoglutide?

7 current trials in our China, Japan and Australia registers name Ecnoglutide (also registered as XW003) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.

Are Ecnoglutide trials recruiting patients?

Yes. 5 of the 7 trials are recruiting: 4 with sites in China, 1 with sites in Japan and 1 with sites in Australia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Ecnoglutide clinical trials?

Hangzhou Sciwind Biosciences Co., Ltd (6) and Verdiva Bio Dev Limited (1). The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Ecnoglutide works or whether it is effective, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Ecnoglutide works or whether it is effective. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Ecnoglutide (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.